Stock Analiz

Korro Bio, Inc. KRRO

Biotechnology: Pharmaceutical Preparations · IPO 2019 · data as of November 13, 2026

$13.61Market cap $187M
Open the interactive analysis →

Korro Bio, Inc. (KRRO) is a healthcare company listed in the US with a market value of about $187M. In the twelve months to September 30, 2026 it had revenue of $1M and net income of -$106M, a net margin of -8214.5%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -30% a year, a 5-year average ROIC of -57%.

About Korro Bio

Korro Bio is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2019. Revenue went from $29M in 2019 to $6M in 2025, a decline of about 22.3% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 3582% over three years (dilution for shareholders). It spends 1026% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S144.6
P/B2.1
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-34.2%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)181.5%
Revenue growth (5 yrs, per year)-29.6%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-2038.9%
ROIC (5-yr avg.)-56.6%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 9 years

Fiscal yearTTM202520242023202220212020201920182017
Revenue$1M$6M$2M$0$0$14M$37M$29M——
Net income-$106M-$117M-$84M-$81M-$58M-$85M-$27M-$19M-$19M-$20M
Free cash flow-$64M-$79M-$78M-$75M-$59M-$79M-$52M$33M-$17M-$16M
EPS (diluted)$-5.94$-12.48$-9.37$-53.08$-227.42$-2.47$-0.82$-2.29$-12.53$-28.79
Net margin-8214.5%-1834.5%-3680.4%——-602.0%-71.7%-64.8%——
ROIC—-101.4%-35.4%-32.9%——-11.2%-12.2%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Korro Bio pay a dividend?

Not currently.

Is Korro Bio a good stock to buy?

We do not give buy or sell advice. Korro Bio scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.